# Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

> **NCT02636582** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 43 (actual)

## Conditions studied

- Breast Ductal Carcinoma In Situ

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Nelipepimut-S Plus GM-CSF Vaccine
- **BIOLOGICAL:** Sargramostim
- **PROCEDURE:** Surgical Procedure

## Key facts

- **NCT ID:** NCT02636582
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-14
- **Primary completion:** 2019-07-22
- **Final completion:** 2023-05-17
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2023-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02636582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02636582, "Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02636582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*